Review of cariprazine in management of psychiatric illness.
Rebecca H CampbellMichael DiduchKristen N GardnerChristopher J ThomasPublished in: The mental health clinician (2018)
Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects. Cariprazine is a novel antipsychotic with unique pharmacodynamic and pharmacokinetic properties. It is both a dopamine type 2 and dopamine type 3 partial agonist with 2 equipotent metabolites, desmethyl cariprazine and didesmethyl cariprazine, of which didesmethyl cariprazine has a half-life of 1 to 3 weeks. The objective of this article is to review the literature regarding efficacy and tolerability of cariprazine in the management of psychiatric disorders to determine its current place in therapy.
Keyphrases
- bipolar disorder
- end stage renal disease
- major depressive disorder
- systematic review
- chronic kidney disease
- ejection fraction
- uric acid
- mental health
- peritoneal dialysis
- prognostic factors
- early onset
- clinical trial
- type diabetes
- ms ms
- open label
- metabolic syndrome
- preterm birth
- replacement therapy
- gestational age
- double blind